case_images: PMC8326622_01
case_images: Case 1 chest computed tomography scan showing bilateral ground-glass opacities with 50% to 75% parenchyma involvement. (A) Image before tocilizumab administration. (B) Image 48 hours after medication, with good reduction of infiltrates.
case_images: 10.1177_23247096211037442-fig1.jpg
case_images: PMC8326622_01_10.1177_23247096211037442-fig1.jpg
case_images: fig1-23247096211037442
case_images: A chest computed tomography (CT) scan was taken (Figure 1) together with laboratorial examinations (Table 1).
case_images: PMC8326622_02
case_images: Case 2 chest computed tomography scan showing bilateral ground-glass opacities and consolidations with 50% to 75% of parenchyma involvement. (A) Image before tocilizumab administration. (B) Image 48 hours after medication.
case_images: 10.1177_23247096211037442-fig2.jpg
case_images: PMC8326622_02_10.1177_23247096211037442-fig2.jpg
case_images: fig2-23247096211037442
case_images: A chest CT (Figure 2) and laboratorial examinations (Table 2) were made.
case_images: PMC8326622_03
case_images: Case 3 chest computed tomography scan showing bilateral ground-glass opacities and consolidations with 25% to 50% of parenchyma involvement. (A) Image before tocilizumab administration. (B) Image 48 hours after medication.
case_images: 10.1177_23247096211037442-fig3.jpg
case_images: PMC8326622_03_10.1177_23247096211037442-fig3.jpg
case_images: fig3-23247096211037442
case_images: A chest CT was performed (Figure 3).